Physician profile
Wayne M Cumbria
NPI 1629048046
$3,745.57
in general payments reported to CMS, 2019-2025
23 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $227 · 2021: $604 · 2022: $591 · 2023: $683 · 2024: $699 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Education: $78.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.27 |
| Education | $78.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $796.98 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $428.54 | 2019-2025 | Rayaldee |
| Amgen INC. | $409.27 | 2022-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $352.64 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $302.48 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $260.99 | 2021-2025 | |
| Vifor Pharma, INC. | $242.98 | 2020-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $184.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $178.94 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $109.91 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $79.24 | 2022-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $76.52 | 2019-2023 | Velphoro, Korsuva |
| Alexion Pharmaceuticals, INC. | $74.48 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $62.64 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $29.96 | 2020-2023 | Benlysta, Jesduvroq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.92 | 2024 | Injectafer |
| Abbott Laboratories | $23.30 | 2023 | Cardiomems |
| Travere Therapeutics, INC. | $23.27 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.94 | 2022 | |
| Ardelyx, INC. | $18.17 | 2024 | Ibsrela |
| Novo Nordisk INC | $17.50 | 2021 | |
| Genzyme Corporation | $16.49 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Cumbria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.